BEDMINSTER, NJ and DUBLIN, IRELAND --(Marketwired - September 03, 2014) - Amarin Corporation plc (
A live audio webcast of the presentation will be available at:
http://wsw.com/webcast/rrshq24/amrn
About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa ® (icosapent ethyl), Amarin's first FDA approved product, is an ultra-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa visit www.vascepa.com . For more information about Amarin visit www.amarincorp.com .
Amarin contact information: Michael Farrell Investor Relations and Corporate Communications Amarin Corporation In U.S.: +1 (908) 719-1315 investor.relations@amarincorp.com Graham Morrell Trout Group In U.S.: +1 (646) 378-2954 gmorrell@troutgroup.com